Automated DNA Extraction System

描述（由申请人提供）：从根本上说，癌症是一种遗传疾病。生殖系变异和体细胞突变不仅影响癌症风险，而且影响这种疾病的治疗，进展和生存。因此，要了解癌症的遗传影响，需要高通量技术支持的大规模基因组研究。基因组数据打开了“黑匣子”，提供了有关使个体易患癌症的分子遗传因素、导致个体肿瘤的特定突变、肿瘤的生理学和患者的生理学的信息。如今，对生殖系遗传学和肿瘤谱进行更全面的评估对于发现个体化药物和个性化治疗的生物标志物至关重要。此共享仪器补助金申请的目的是资助购买高通量DNA提取系统。所需的DNA提取平台是来自生物标本自动化处理领域两家成熟供应商Qiagen和Tecan的集成解决方案。具体而言，Qiagen AutoPure LS系统可自动纯化DNA库和基于人群的遗传关联研究所需的档案质量、高分子量DNA。Qiagen AutoPure系统将与Tecan EVO 150液体处理平台集成，该平台将能够评估DNA产量、质量、标准化并在二维条形码低温管中等分成所需体积。本申请中描述的各种项目的具体目标各不相同，然而它们都共同需要高通量系统，该系统可以产生高质量DNA以支持包括全基因组关联研究（GWAS）、用于研究成人神经胶质瘤发病的环境因素的大型病例系列、前列腺癌生物标志物发现、基因分型和直接测序以研究男性HPV感染的自然史的努力。这一工具的预计使用情况表明，它将很好地用于所述项目，利用74%的能力。剩余的能力将用于支持其他癌症中心的研究人员和倡议，如全面癌症护理机构一般银行协议。仪器将在组织核心共享资源设施内存放和操作。癌症中心将通过购买超过54，000美元的年度服务合同，为这两个系统的护理和维护提供重要的机构支持。该提案中描述的主要用户是NIH资金超过2400万美元的主要研究人员。

DESCRIPTION (provided by applicant): Fundamentally cancer is a genetic disease. Germline variations and somatic mutations influence not only cancer risk but also impact the treatment, progression, and survival of this disease. Thus, to understand the genetic influence of cancer, large-scale genomic based research supported by high-throughput technologies is a necessity. Genomic data opens the "black box" and provides information about the molecular genetic factors that predispose individuals to cancer development, the specific mutations that gave rise to an individual tumor, the physiology of a tumor, and the physiology of the patient. Today a more comprehensive evaluation of germline genetics and tumors profiles is essential for the discovery of biomarkers for individualized medicine and personalized therapy. The purpose of this Shared Instrumentation Grant application is to fund the purchase of a high-throughput DNA extraction system. The requested DNA extraction platform is an integrated solution from two well established vendors in biospecimen automated processing, Qiagen and Tecan. Specifically, the Qiagen AutoPure LS system provides automated purification of archival quality, high molecular weight DNA that is required for DNA banking and population-based genetic association studies. The Qiagen AutoPure system will be integrated with a Tecan EVO 150 liquid handling platform that will enable the assessment of DNA yield, quality, normalization and aliquoting into desired volumes in 2D bar-coded cryogenic tubes. The specific aims for various projects described in this application vary, however they all share the common need for a high-throughput system that can generate high quality DNA to support efforts including genome-wide association studies (GWAS), large case series for studying environmental factors on the onset of adult glioma, prostate cancer biomarker discovery, genotyping and direct sequencing to study the natural history of HPV infection in men. Projected usage of this instrument indicates that it will be well used with the described projects utilizing 74% of capacity. Remaining capacity will be utilized to support other Cancer Center investigators and initiatives such as the Total Cancer Care institutional general banking protocol. The instrument will be housed and operated within the Tissue Core Shared Resource facility. The Cancer Center will provide significant institutional support for this instrumentation by purchasing over $54,000 in yearly service contracts to facilitate the care and maintenance of the both system. Major users described in this proposal are principal investigators on over $24-million dollars in NIH funding.